Mucopolysaccharidosis I – Diagnostics – Overview of Information and Clinical Research

Diagnosing Mucopolysaccharidosis Type I requires a combination of careful clinical observation, specialized laboratory testing, and genetic analysis to confirm the presence of this rare inherited condition and determine its severity.

Introduction: Who Needs Diagnostic Testing for MPS I

When a child begins showing certain physical changes or developmental concerns, parents and doctors need to consider whether these signs point to a deeper health issue. Mucopolysaccharidosis Type I, often shortened to MPS I, is a rare genetic condition that can be difficult to recognize early because babies typically appear completely normal at birth. The condition develops gradually as harmful substances build up inside the body’s cells over time.^[1]

Diagnostic testing becomes important when certain warning signs appear. These might include a child who has frequent upper respiratory infections, unusual facial features that become more pronounced over time, a curved lower spine, or an enlarged belly. Some infants may have a soft bulge near the belly button or in the groin area, known as hernias. Parents might also notice their child has recurring ear infections, breathing difficulties during sleep, or joints that seem stiff and hard to move.^[1]

Early diagnosis matters tremendously because starting treatment sooner rather than later can make a significant difference in how the disease progresses. In severe forms of MPS I, children who don’t receive treatment typically face serious complications within the first few years of life. The attenuated, or milder forms, may not show obvious symptoms until a child is between three and ten years old, but catching the condition early still offers better chances for managing symptoms and preventing damage.^[4]

Many regions now include MPS I in their newborn screening programs, which means testing happens automatically for all babies shortly after birth. When screening flags a potential problem, parents shouldn’t panic—the screening test is just the first step, not a diagnosis. Further testing is always needed to confirm whether the child actually has the condition. Detecting MPS I through newborn screening allows treatment to begin before symptoms appear, which can lead to better outcomes, improved growth, and healthier development.^[5]

⚠️ Important

If your baby’s newborn screening shows abnormal results for MPS I, remember that this is not a final diagnosis. Many babies flagged by screening turn out not to have the condition. However, it’s crucial to complete all follow-up testing as quickly as possible so that if your child does have MPS I, treatment can start right away to prevent or delay serious health problems.

Classic Diagnostic Methods for MPS I

Confirming a diagnosis of MPS I involves several different types of tests that work together to paint a complete picture. Doctors typically start with tests that measure specific substances in the body, then move to more precise genetic testing to confirm the diagnosis and understand how severe the condition might be.

Enzyme Activity Testing

The most fundamental test for MPS I measures the activity of a specific enzyme called alpha-L-iduronidase, often shortened to IDUA. This enzyme’s job is to break down complex sugar molecules called glycosaminoglycans, or GAGs. In people with MPS I, this enzyme either doesn’t work properly or is missing entirely, which causes GAGs to accumulate inside cells and damage tissues throughout the body.^[1]

The enzyme activity test typically uses a blood sample, though it can also be performed on other types of cells. Laboratory technicians measure how much functional IDUA enzyme is present. When the enzyme activity falls below normal levels or is completely absent, this strongly suggests MPS I. This test is quite reliable for confirming the presence of the disease, but it doesn’t tell doctors whether a child has the severe or attenuated form—that requires additional investigation.^[4]

Glycosaminoglycan (GAG) Measurement

Another important diagnostic test measures the amount of GAGs in the urine. Since people with MPS I cannot properly break down these sugar molecules, excess amounts spill into the urine where they can be detected and measured. The test specifically looks for elevated levels of two types of GAGs: dermatan sulfate and heparan sulfate. Finding high concentrations of these substances supports the diagnosis of MPS I.^[2]

While this test is useful, it’s not perfect on its own. GAG levels can sometimes be elevated in other conditions, and in very mild cases of MPS I, GAG levels might not be dramatically high. That’s why doctors combine this test with enzyme activity measurements and genetic testing rather than relying on any single result.^[4]

Genetic Testing

Genetic testing looks for specific changes, called mutations or pathogenic variants, in the IDUA gene. This gene contains the instructions for making the IDUA enzyme. MPS I happens when a person inherits two faulty copies of this gene—one from each parent. This pattern is called autosomal recessive inheritance, meaning both parents typically carry one changed copy of the gene but don’t have symptoms themselves.^[2]

Finding the exact genetic changes helps doctors in several important ways. First, it confirms the diagnosis beyond any doubt. Second, it helps predict whether the condition will be severe or attenuated, though this isn’t always straightforward since the same genetic changes can sometimes cause different levels of severity in different people. Third, genetic information helps families understand their risk of having another child with MPS I and allows other family members to find out if they carry the gene change.^[4]

Physical Examination and Clinical Assessment

Doctors also rely heavily on careful physical examination to recognize the characteristic signs of MPS I. They look for distinctive facial features often described as “coarse,” which might include a large head, widely spaced eyes, a flattened bridge of the nose, thick lips, and a large tongue. The examination includes checking for an enlarged liver and spleen, examining the spine for abnormal curvature, testing joint mobility, and listening to the heart for valve problems.^[3]

Eye examinations often reveal clouding of the cornea, which is the clear front part of the eye. This cloudiness happens because GAGs accumulate in the cornea and can significantly affect vision if left untreated. Hearing tests are also important since many people with MPS I develop hearing loss over time due to repeated ear infections and GAG buildup in the structures of the ear.^[1]

Imaging Studies

X-rays and other imaging tests help doctors see the skeletal changes that are typical in MPS I. Children with this condition develop a pattern of bone abnormalities called dysostosis multiplex, which affects multiple bones throughout the body. These changes appear on X-rays and include abnormally shaped vertebrae in the spine, shortened and thickened bones in the arms and legs, and joints that don’t form properly.^[1]

Additional imaging might include ultrasound of the heart to check for valve problems, brain scans to look for fluid buildup called hydrocephalus, or scans of the spine to check for narrowing of the spinal canal that could compress the spinal cord. These tests don’t diagnose MPS I by themselves, but they help doctors understand how much the condition has already affected different body systems.^[3]

Distinguishing MPS I from Other Conditions

Part of the diagnostic process involves making sure the symptoms aren’t caused by something else. Several other types of mucopolysaccharidoses exist, each caused by deficiency of a different enzyme. MPS II, also called Hunter syndrome, can look very similar to MPS I but involves a different enzyme called iduronate-2-sulfatase. Genetic testing and enzyme activity measurements can distinguish between these conditions.^[6]

Other genetic conditions can also cause some overlapping features, such as developmental delays, distinctive facial features, or bone abnormalities. The combination of enzyme testing, GAG measurements, and genetic analysis usually makes it possible to identify MPS I specifically and rule out other diagnoses.

Diagnostics for Clinical Trial Qualification

When families consider enrolling in clinical trials testing new treatments for MPS I, additional diagnostic evaluations often become necessary. Clinical trials have specific requirements about which patients can participate, and detailed baseline testing helps researchers measure whether experimental treatments are working.

Baseline Disease Severity Assessment

Before someone can join a clinical trial, researchers need to thoroughly document the current state of their disease. This creates a starting point against which future changes can be measured. The assessment typically includes comprehensive testing of physical abilities, such as how far the person can walk in six minutes, how well their lungs work when measured through pulmonary function tests, and how well their heart pumps blood as seen on an echocardiogram.^[4]

For children, developmental testing becomes especially important. Psychologists or developmental specialists use standardized tests to measure cognitive abilities, language skills, and developmental milestones. This information helps determine whether someone qualifies for a trial and later shows whether treatment affects intellectual development. Many trials specifically require participants to have either severe or attenuated MPS I, so this assessment helps place each person in the right category.^[4]

Genetic Confirmation

Clinical trials almost always require genetic confirmation that participants actually have MPS I and not a different but similar condition. This means documenting the specific mutations in the IDUA gene through DNA testing. Some trials might only accept participants with certain types of genetic changes, particularly when testing treatments designed to work with specific mutations. Families typically receive genetic counseling to help them understand their child’s specific genetic findings and what they mean for prognosis and treatment options.^[4]

Biomarker Measurements

Clinical trials often measure biomarkers—biological signs that can be measured objectively—to track disease activity and treatment response. For MPS I trials, important biomarkers include urine GAG levels, which show how much of the harmful substances are building up, and blood GAG levels. Researchers might also measure specific proteins or inflammatory markers that indicate cell damage or immune system activation.^[4]

Some newer trials use advanced imaging techniques to measure GAG deposits in specific organs or to track structural changes in the brain over time. These detailed measurements help researchers understand not just whether someone improves clinically, but what’s happening at the cellular and tissue level.

Functional Assessments

Clinical trials need objective ways to measure whether treatments improve daily functioning. This might include standardized questionnaires that parents or patients complete about quality of life, ability to perform self-care tasks, pain levels, and social participation. For children, assessments might measure school performance, social skills, and behavioral challenges.

Physical therapists or occupational therapists often perform standardized tests of joint mobility, muscle strength, and fine motor skills. These assessments create measurable data points that can show whether experimental treatments lead to meaningful improvements in how people with MPS I function in their daily lives.

⚠️ Important

Clinical trial participation requires extensive testing and frequent monitoring visits, which can be demanding for families. However, trials offer access to promising new treatments before they become widely available and contribute to advancing knowledge that helps future patients. Families should discuss the potential benefits and burdens carefully with their medical team before deciding whether trial participation is right for them.

Monitoring Tests During Trials

Once enrolled in a clinical trial, participants undergo regular testing to monitor both treatment effects and safety. This typically includes repeated enzyme activity measurements, GAG levels, physical examinations, and imaging studies at scheduled intervals. The frequency and types of tests depend on the specific trial protocol.

Safety monitoring is a major focus, with regular blood tests to check liver and kidney function, blood cell counts, and signs of immune system reactions to treatment. Some treatments require antibody testing to see if the body is developing immune responses against the therapy being studied. All these measurements help researchers determine whether experimental treatments are safe and effective.^[12]

Prognosis and Survival Rate

Prognosis

The outlook for people with MPS I depends heavily on which form they have and when treatment begins. For those with severe MPS I, historically called Hurler syndrome, the prognosis without treatment was quite poor. These children typically experienced rapid progression of symptoms, severe intellectual disability, and death usually within the first ten years of life, most often from heart and breathing complications.^[4]

However, when children with severe MPS I receive early treatment—particularly hematopoietic stem cell transplantation, often called bone marrow transplant—the outlook improves dramatically. Treatment started before significant symptoms develop can preserve intellectual function and extend life expectancy considerably, though it cannot reverse skeletal abnormalities that have already formed. The timing of treatment is absolutely critical, with better outcomes seen when transplantation happens before age two years, ideally in the first year of life. Disease burden at the time of treatment significantly influences the final outcome.^[4]

For people with attenuated MPS I, the disease progresses more slowly and varies greatly from person to person. Some individuals with the mildest forms can have normal intelligence and a normal lifespan, though they may face significant challenges from progressive joint problems, heart valve disease, and respiratory complications. Others with more serious attenuated disease may experience life-threatening complications in their second or third decade of life. Learning disabilities and psychiatric problems can occur even when overall intelligence remains in the normal range.^[4]

Heart disease and airway obstruction represent the major causes of death in both severe and attenuated forms of MPS I. Progressive damage to heart valves, narrowing of airways due to GAG deposits, and complications from skeletal abnormalities affecting the chest all contribute to these serious outcomes. Regular monitoring and management of these complications are essential for everyone with MPS I, regardless of severity.^[1]

Survival Rate

Severe MPS I affects approximately 1 in every 100,000 newborns, while attenuated forms are less common, occurring in about 1 in 500,000 births.^[1] Without treatment, children with severe MPS I typically do not survive past late childhood, with most deaths occurring within the first ten years of life due to cardiorespiratory failure.^[4]

With modern treatment approaches, particularly early bone marrow transplantation, children with severe MPS I generally have increased lifespan compared to untreated children. While exact survival statistics vary based on multiple factors including age at treatment and disease severity at diagnosis, early intervention has transformed this condition from one that was uniformly fatal in childhood to one where many affected individuals can survive into adulthood with appropriate care.^[9]

People with attenuated MPS I have a wide range of life expectancies depending on disease severity. Some individuals with the mildest forms may have a normal lifespan, though they often face progressive disability from joint and organ complications. Those with more significant attenuated disease may face serious, life-threatening complications leading to death in the second or third decade of life, though again, early treatment and careful management of complications can extend survival.^[4]

#1 Clinical Trials Search in Europe